Welcome to our dedicated page for Artivion news (Ticker: AORT), a resource for investors and traders seeking the latest updates and insights on Artivion stock.
Artivion, Inc. (AORT) pioneers life-saving medical devices for aortic disease treatment, serving cardiac and vascular specialists worldwide. This dedicated news hub provides investors and medical professionals with timely updates on company developments, clinical advancements, and strategic initiatives.
Access official press releases, earnings reports, and regulatory updates in one centralized location. Track innovations across Artivion's core product lines including aortic stent grafts, surgical sealants, and implantable tissues. Our curated news collection helps stakeholders monitor clinical trial progress, partnership announcements, and market expansion efforts.
Key updates include FDA clearances, international regulatory milestones, and peer-reviewed study results from ongoing trials. Discover how Artivion's technologies continue to reshape treatment protocols in complex cardiovascular surgeries through verified clinical outcomes and surgeon testimonials.
Bookmark this page for continuous access to verified information about AORT's medical advancements. Check regularly for new developments impacting the future of aortic disease management and surgical innovation.
Artivion (NYSE: AORT) announced the first patient has been treated in the ARTIZEN pivotal trial evaluating the Arcevo LSA Hybrid Stent Graft System for acute and chronic aortic arch pathologies. The prospective, multicenter, non-randomized study will enroll 132 participants across up to 30 U.S. and European centers, with follow-up to five years and emphasis on 1-year outcomes. Primary combined safety and efficacy endpoints include all-cause mortality, new permanent disabling stroke, new permanent paraplegia/paraparesis, unanticipated aortic reoperation in the treated segment, and left subclavian artery occlusion. Artivion says the trial is intended to support a U.S. PMA submission and estimates an incremental $80 million U.S. market opportunity for Arcevo as soon as 2029.
Artivion (NYSE: AORT) will participate in the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at the Lotte New York Palace Hotel.
The company's fireside chat begins at 8:00 a.m. ET. A live webcast will be available on Artivion's Investors page at www.artivion.com, with an archived copy accessible for 90 days after the event.
Artivion (NYSE: AORT) will release third quarter 2025 financial results on Thursday, November 6, 2025 after market close, with a teleconference and live webcast at 4:30 p.m. ET.
Pat Mackin, Chairman, President and CEO, will host the call and Q&A. To join live, dial 201-689-8261 a few minutes before 4:30 p.m. ET. A replay will be available about one hour after the event via toll-free 877-660-6853 or 201-612-7415 using conference number 13755945. The live webcast and replay and the earnings press release with financial and statistical information will be accessible in the Investors section at www.artivion.com under Webcasts & Presentations.
Artivion (NYSE:AORT) presented late-breaking data from the AMDS PERSEVERE and PROTECT trials at the 39th EACTS Annual Meeting on October 13, 2025. The PERSEVERE 30-day analysis (n=40 with organ malperfusion) showed visceral malperfusion resolution in 83% and renal malperfusion resolution in 74%, with radiographic renal resolution in all affected patients. The PROTECT real-world registry (n=141) reported outcomes consistent with PERSEVERE and DARTS, including renal failure requiring dialysis 4.2%, unanticipated reoperation 1.4%, no paralysis/paraparesis, and 95.3–100% positive aortic remodeling in zones 1–3.
Artivion (NYSE:AORT), a cardiac and vascular surgery company specializing in aortic disease, announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. The company will engage in a fireside chat on September 10, 2025, at 2:35 pm ET at the Sheraton New York Times Square Hotel.
Investors can access the live webcast through Artivion's website at www.artivion.com in the Investors section. The webcast recording will remain available for 90 days following the presentation.
Artivion (NYSE:AORT) reported strong Q2 2025 financial results with revenue reaching $113.0 million, marking a 15% increase from Q2 2024. The company achieved net income of $1.3 million ($0.03 per share) and non-GAAP net income of $10.7 million ($0.24 per share).
Key highlights include 33% growth in Adjusted EBITDA to $24.8 million, significant revenue growth across product lines with On-X and stent grafts both up 24%, and the exchange of $99.5 million in convertible senior notes for common stock. The company received FDA IDE approval for the ARTIZEN pivotal trial for Arcevo LSA.
Given strong performance, Artivion raised its 2025 guidance, now expecting constant currency growth of 12-14% with revenues between $435-443 million and adjusted EBITDA growth of 21-28% ($86-91 million).
Artivion (NYSE:AORT), a cardiac and vascular surgery company, announced its participation in two upcoming investor conferences. The company will present at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025, at 10:30 a.m. ET, with a live webcast available on their website. Additionally, management will participate in investor meetings at the 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 12, 2025, though no webcast will be available for this event.
Artivion (NYSE: AORT), a cardiac and vascular surgery company specializing in aortic disease, has scheduled its second quarter 2025 financial results release for Thursday, August 7, 2025, after market close.
The company will host a teleconference call and live webcast at 4:30 p.m. ET featuring CEO Pat Mackin, followed by a Q&A session. Participants can dial 862-298-0702 to join the call, with replay available at 877-660-6853 or 201-612-7415 using conference number 13754541.
The webcast and earnings press release will be accessible through the Investors section of www.artivion.com.
Artivion (NYSE: AORT) has successfully closed transactions to exchange approximately $99.54 million of its 4.250% Convertible Senior Notes due 2025 for 4,334,347 shares of common stock. The company also made a cash payment of $1.7 million for accrued and unpaid interest to the note holders. Following these transactions, only $0.46 million in aggregate principal amount of the Notes remains outstanding.
CEO Pat Mackin emphasized that this effective retirement of convertible notes represents a significant milestone in strengthening Artivion's financial position, reducing leverage ratios, and enhancing balance sheet flexibility. J. Wood Capital Advisors LLC served as financial advisor for these exchange transactions.
FAQ
What is the current stock price of Artivion (AORT)?
What is the market cap of Artivion (AORT)?
